Opinion

Video

Tisotumab Vedotin for Patients With Cervical Cancer

Author(s):

Claire Friedman, MD,Emily Davan, RN

Comprehensive insights on the journey of a patient with cervical cancer and treatment options upon progression, with a focus on tisotumab vedotin.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of Dr. Salani.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
A panel of 3 experts on cervical cancer seated on chairs in a studio
A panel of 3 experts on cervical cancer seated on chairs in a studio
Linda Ryan, a patient advocate
A panel of 3 experts on cervical cancer seated on chairs in a studio
A panel of 3 experts on cervical cancer seated on chairs in a studio
A panel of 3 experts on cervical cancer seated on chairs in a studio
A panel of 3 experts on cervical cancer seated on chairs in a studio
Related Content
Breyanzi demonstrated a 95.5% response rate among in relapsed/refractory marginal zone lymphoma: © stock.adobe.com.
June 17th 2025

Breyanzi Shows Durable Responses in R/R Marginal Zone Lymphoma

Spencer Feldman
Breyanzi demonstrated a 95.5% response rate among patients with relapsed/refractory marginal zone lymphoma, as well as a durable safety.
A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More
January 22nd 2024

A Chance of Cure for Cervical Cancer, Lymphedema Treatment Act and More

Alex Biese Brielle Benyon
We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.
A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST: © stock.adobe.com.
May 1st 2025

First Patient Dosed in Trial of Ziftomenib for Advanced GIST

Spencer Feldman
A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following progression on Gleevec.
Kate Weissman, a gynecologic cancer survivor
November 30th 2023

Fertility Research ‘Long Overdue’ for Patients With Cervical Cancer

Alex Biese
Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’
Image of Clinical trial text.
April 12th 2025

First Patient Dosed With KSQ-004EX In Solid Tumor Clinical Trial

Alex Biese
KSQ-004EX is being evaluated in solid tumors including melanoma, non-small cell lung, head and neck, colorectal, pancreatic and cervical cancer.
Image of doctor consulting a woman.
February 28th 2025

Chemoradiation Benefits for Cervical Cancer May Decline After Age 80

Spencer Feldman
Chemoradiation improves survival in cervical cancer patients, but benefits may decline after age 80, according to a study using SEER data.